Abbott Laboratories 2012 Annual Report Download - page 20

Download and view the complete annual report

Please find page 20 of the 2012 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

Through the years, AbbVie’s leading pharmaceutical
brands have made a life-changing dierence for millions
of patients around the world. The company has a
broad portfolio of products that hold strong category-
leadership positions and compete in markets that oer
signicant growth potential. It has a strong record of
outstanding operating performance and will continue to
benet from a strong nancial foundation, a compelling
late-stage pipeline with several assets that represent
billion-dollar-plus peak-year revenue potential, and a
highly experienced leadership team dedicated to creating
a successful future.
A Powerful Product Portfolio
Humira
remains the cornerstone of AbbVie’s portfolio
and will continue to be a strong growth driver. Since it
was launched as a treatment for rheumatoid arthritis in
2003,
Humira
has steadily added indications. In 2012,
the addition of new indications for patients — ulcerative
colitis in both the United States and Europe, plus axial
spondyloarthritis and pediatric Crohn’s disease in
Europe — brought
Humira’s
total to nine separate
indications treated. More than 600,000 people around
the world count on
Humira
to provide some relief
from their chronic conditions.
AbbVie will continue to build on the success of
Humira
with additional research in autoimmune diseases. These
diseases result from underlying defects in a patient’s
immune system, which cause it to attack healthy organs,
•
AndroGel
is the leading testosterone replacement
therapy.
•
Lupron Depot
is the leading hormone therapy for the
palliative treatment of advanced prostate cancer
and is also indicated for endometriosis, uterine broids
and central precocious puberty.
•
Kaletra
and
Norvir
are leading protease inhibitors
to treat HIV.
•
Synthroid
is the number-one prescribed brand for
thyroid disease.
•
Synagis
is the only approved product for the prevention
of Respiratory Syncytial Virus (RSV).
• And
Creon
is the leading pancreatic enzyme therapy
for exocrine pancreatic insuciency, a condition
associated with cystic brosis and chronic pancreatitis.
AbbVie’s portfolio of biologics and other
compounds addresses some of the world’s most
complex medical needs, building AbbVie
disease-state leadership through products like
Humira
,
Lupron
,
Synagis
and
Kaletra
.
Abbott 2012 Annual Report
18
tissues and cells. For reasons not fully understood, the
prevalence of autoimmune disease has been steadily
rising. Collectively, autoimmune diseases aect as many
as 43 million people. Its immunology pipeline includes
development work in oral disease-modifying therapies
and biologics, as well as proprietary combination
biologic agents.
In addition to
Humira
, AbbVie has a number of specialty-
care products that hold market-leading positions.